Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight

Song, Xueqin; Fan, Xiaoduo; Song, Xiu–Peng; Zhang, Jianjiang; Zhang, Wei; Li, Xue; Gao, Jinsong; Harrington, Amy; Ziedonis, Douglas M.; Lv, Luxian

doi:10.1016/j.schres.2013.07.044

Cited by 75 publications

(40 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AAPs have also been associated with perturbations in the secretion and/or action of several hormones (insulin, leptin, ghrelin, adiponectin) and neuropeptides (NPY, AgRP, POMC) involved in the control of satiety and feeding behaviors (Jin et al 2008;Sentissi et al 2009;Song et al 2013). Results are, however, inconsistent; for example, Davoodi et al (2009) demonstrated increased meal size with acute OLA administration in rats was not associated with changes in NPY or POMC mRNA levels.…”

Section: Discussion/conclusionmentioning

confidence: 99%

Atypical antipsychotics and effects on feeding: from mice to men

et al. 2016

View full text Add to dashboard Cite

The findings from this review indicate that the varying levels of AAP-related weight gain reflect changes in both appetite and feeding behaviors, which differ by type of AAP. However, inconsistencies exist among the studies (both human and rodent) that may reflect considerable differences in study design and methodology. Future studies examining underlying mechanisms of antipsychotic-induced weight gain are recommended in order to develop strategies addressing the serious metabolic side effect of AAPs.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Atypical antipsychotics and effects on feeding: from mice to men

et al. 2016

View full text Add to dashboard Cite

show abstract

“…100 Furthermore, similarly increased levels of IL-1β, IL-6, TNF-α, but also importantly elevated adiponectin levels were detected in drug naïve, first episode patients with schizophrenia and normal weight, as compared with obese or overweight individuals without schizophrenia, which suggest a potential unique pro-inflammatory role of adiponectin in patients with schizophrenia, leading to later metabolic syndrome. 101 To explain this comorbidity between schizophrenia and diabetes in genetic terms, linkage studies as well as genome-wide association studies (GWAS) are applied to shed light into this direction. As linkage studies are concerned, one could start with probing the gene involved in both glucose and dopamine pathways.…”

Section: Genetic Predisposition For Comorbidity Schizophrenia and Typmentioning

confidence: 99%

Schizophrenia and type 2 diabetes mellitus

et al. 2018

View full text Add to dashboard Cite

S chizophrenia is associated with increased risk for type 2 diabetes mellitus, resulting in elevated cardiovascular risk and limited life expectancy, translated into a weighted average of 14.5 years of potential life lost and an overall weighted average life expectancy of 64.7 years. The exact prevalence of type 2 diabetes among people with schizophrenia varies across studies and ranges 2-5fold higher than in the general population, whereas the aetiology is complex and multifactorial. Besides common diabetogenic factors, applied similarly in the general population, such as obesity, hyperlipidemia, smoking, hypertension, poor diet and limited physical activity, the co-occurrence of schizophrenia and diabetes is also attributed to unique conditions. Specifically, excessive sedentary lifestyle, social determinants, adverse effects of antipsychotic drugs and limited access to medical care are considered aggravating factors for diabetes onset and low quality of diabetes management. Schizophrenia itself is further proposed as causal factor for diabetes, given the observed higher prevalence of diabetes in young patients, newly diagnosed with schizophrenia and unexposed to antipsychotics. Furthermore, studies support genetic predisposition to diabetes among people with schizophrenia, suggesting shared genetic risk and disclosing a number of overlapped risk loci. Therefore, special attention should be paid in preventing diabetes in people with schizophrenia, through intervention in all possible modifiable risk factors. Implementation of careful antipsychotic prescription, provision of adequate motivation for balanced diet and physical activity and facilitating access to primary health care, could serve in reducing diabetes prevalence. On the other hand, increasing calls are made for early diagnosis of diabetes, application of the appropriate anti-diabetic therapy and strict inspection of therapy adherence, to limit the excess mortality due to cardiovascular events in people with schizophrenia. Moreover, population health programs could help counseling and preventing diabetes risk, additionally to early screening and diagnosis set, aiming to reduce disparities in populations. Finally, mental health-care providers might greatly promote offered health services to patients with schizophrenia, through a holistic individualized approach, considering additionally the physical health of the patients and working closely, preventively and therapeutically, in collaboration with the physicians and diabetologists.

show abstract

“…The results from recently published controlled study showed elevated levels of IL-1β, IL-6, and TNF-α in these patients. The levels of adiponectin were significantly higher in the normal weight, drug naive patients with first episode of schizophrenia; the levels were significantly lower in the otherwise healthy obesity group [10] .…”

Section: Metabolic Disturbances Associated With Diseasementioning

confidence: 81%

Metabolic disturbances in schizophrenia: Association with disease and drugs

Patil¹

2013

iosrphr

View full text Add to dashboard Cite

Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight

Cited by 75 publications

References 42 publications

Atypical antipsychotics and effects on feeding: from mice to men

Atypical antipsychotics and effects on feeding: from mice to men

Schizophrenia and type 2 diabetes mellitus

Metabolic disturbances in schizophrenia: Association with disease and drugs

Contact Info

Product

Resources

About